Navigation Links
ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
Date:1/15/2009

IRVINE, Calif., Jan. 15 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced that ISTA's New Drug Application (NDA) for Bepreve(TM) (bepotastine ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA). The Company is seeking approval for Bepreve as an eye drop treatment for ocular itching associated with allergic conjunctivitis. The Company expects a standard review of ten months and has been given a user fee action date of September 12, 2009.

ISTA's Phase III clinical studies with Bepreve demonstrated highly statistically significant reductions in the primary endpoints of ocular itching. In addition, the results showed Bepreve had a statistically significant effect on the rapidity of response and on additional signs or symptoms of ocular allergy, including improvement in nasal symptoms. There were no serious ocular adverse events reported in patients dosed with Bepreve.

About Bepreve(TM) (bepotastine ophthalmic solution)

Assuming approval from the FDA, Bepreve would participate in ISTA's largest market to date. IMS Health estimates the U.S. ocular allergy market generated approximately $560 million in sales in 2007. Bepreve is a non-sedating, highly selective antagonist of the histamine (H1) receptor. It has a stabilizing effect on mast cells and it suppresses the migration of eosinophils into inflamed tissues. The compound's primary mechanisms of action are believed to make it an effective treatment against the signs and symptoms of allergic conjunctivitis.

Bepotastine was approved in Japan for use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the b
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... 2014.  Provided below are the highlights: , ... quarter compared with the prior year. Reported sales increased ... , Net earnings per diluted share as reported (EPS) ... of 2013. Adjusted EPS was $2.57, an increase of ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, Inc. ... of medication and supply management solutions and analytics ... Thursday, July 31, to discuss the Company,s Second ... Second Quarter 2014 earnings conference call and webcastWhen: ... , Randall Lipps, chairman, president and chief executive ...
(Date:7/24/2014)... VANCOUVER, British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today ... the company,s fiscal year from December 31 to June 30. ... before September 30, 2014. Jeffrey Bacha , ... year end is an important step in achieving our goal ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
... 14, 2010 Cannabis Science, Inc. (OTC Bulletin Board: ... cannabis products, is pleased to announce it has signed a ... of operations in Denver, Colorado. The 6,600 sq. ft. core ... dedicated to housing executive offices, administrative personnel, as well as ...
... 2010 Pfizer Inc. (NYSE: PFE ) announced ... A. Lorch, 68, who has served as an independent director ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) The Board,s ... been a valuable, independent voice on the Pfizer Board for ...
Cached Medicine Technology:Cannabis Science Signs Lease for New 6,600 sq. ft. Corporate Headquarters and Laboratory Facility 2Cannabis Science Signs Lease for New 6,600 sq. ft. Corporate Headquarters and Laboratory Facility 3Pfizer Board of Directors Elects George A. Lorch Non-Executive Chairman 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 Drexel University ... D. Weber, MD, MS, FACP, has been appointed vice dean ... will join Drexel from The Commonwealth Medical College, where she ... dean for clinical affairs, and professor of medicine. , ... Commonwealth Medical College, Weber had a major role in many ...
(Date:7/25/2014)... News) -- Babies seem to learn even before they,re ... women are 34 weeks pregnant, their unborn babies can ... a familiar nursery rhyme, the researchers report. "The ... in the developing fetus," Charlene Krueger, nursing researcher and ... Nursing, said in a university news release. "This research ...
(Date:7/25/2014)... sent patients to designated cardiac receiving centers dramatically increased ... in Arizona, according to a study published online yesterday ... , "We knew lives would be saved if the ... arrest care and we were able to get cardiac ... done for Level 1 trauma patients," said lead study ...
(Date:7/25/2014)... Parkulture is proud to ... parkour instructor, Jared “JJ” Woods, will be competing on ... Ninja Warrior. The show will premiere on local affiliates ... rerun on the new Esquire Network on Tuesday, July ... has been balancing careers as a professional stuntman for ...
(Date:7/25/2014)... 2014 In today’s technological era, every ... supporting devices. This benefits the organization in various ways. ... attacks which can destroy the confidential information and processes ... and Compliance (EGRC) manage and protect the enterprise from ... cause loss in dollars to the comp may. The ...
Breaking Medicine News(10 mins):Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 3Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6
... may be the way to make a living, but it ... new study from the Universit de Montral, office-workers have become ... activity may partly explain the rise in obesity. Their findings, ... , may have health implications for the millions of people ...
... , MONDAY, Oct. 4 (HealthDay News) -- Children whose ... brain chemical serotonin because of gene mutations may be ... later in life, Norwegian researchers report. Serotonin ... important role during development, especially in the development of ...
... of chronic diseases to the top of the EU ... Kidney Health , the EU Diabetes Working Group and ... the European Parliament, together with representatives of health professionals and ... these chronic diseases urgently, they threaten the "Europe 2020 strategy", ...
... CHANGES , The use of a nasal continuous positive ... may cause craniofacial changes in adults with obstructive sleep ... Vancouver, BC, Canada, analyzed baseline and follow-up radiographs from ... for a minimum of 2 years. Changes in craniofacial ...
... SAN FRANCISCO Implementing a Medical Home practice model ... provide comprehensive care to more patients, and to offer ... with their doctors, recommendations and reduce emergency room visits ... 4, 2010, at the American Academy of Pediatrics (AAP) ...
... -- A new vaccine added to standard therapy appears to ... the most deadly form of brain cancer, according to a ... University of Texas MD Anderson Cancer Center. The vaccine ... most aggressive form of the disease. "About a third ...
Cached Medicine News:Health News:Is your job making you fat? 2Health News:New Clues to Possible Genetic Basis for ADHD 2Health News:New Clues to Possible Genetic Basis for ADHD 3Health News:Heart, kidney, diabetes and cancer MEP groups league against chronic disease to seek European commitment 2Health News:Heart, kidney, diabetes and cancer MEP groups league against chronic disease to seek European commitment 3Health News:Chest news briefs: CPAP may cause facial changes 2Health News:Medical home care approach improves efficiency and care at clinic for low-income families 2Health News:Duke vaccine extends survival for patients with deadly brain cancers 2Health News:Duke vaccine extends survival for patients with deadly brain cancers 3
... Goldmann standard automatic or manual ... with white/white, blue/yellow or red/white stimuli/background ... or classic 4-2 threshold strategy. Examination ... grids (including 30-2, 24-2, and 10-2). ...
The Oculus easyfield is an exciting new compact perimeter to do automatic static perimetry up to 30 degrees eccentricity. It has been designed for the combined use as a visual field screener and peri...
... Designed around the patented Interzeag ... 301 sets the trend in ... Ideal for routine screening and ... performance, accuracy and quality of ...
Focus Toric Monthly lenses. All the advantages of Focus Monthly lenses, now available for patients with astigmatism. Recommended for daily wear. Also approved for extended wear (1-7 days)....
Medicine Products: